HOME >> BIOLOGY >> NEWS
Triptolide: A potential drug for polycystic kidney disease

rmed, as sensed by fluid flow in the tubule. Fluid flow bends the primary cilium, giving a signal to stop cell growth. PKD is caused by a mutation in the PKD1 or PKD2 gene causing the cells to miss the stop growing signal, allowing them to keep growing, and thus generating a cyst.

In collaboration with Stefan Somlo, M.D., Chief of Nephrology at Yale School of Medicine, who discovered the PKD2 gene, triptolide was tested in a mouse model of PKD. Both fewer and smaller kidney cysts formed in mice lacking PKD1 when they were treated with therapeutic amounts of triptolide.

Our research shows that triptolide, an active ingredient of the TCM Lei Gong Teng, markedly decreases cyst formation in a mouse model of this most common genetic lethal kidney disease, Crews said. Our results offer a novel therapeutic approach to this deadly disease and highlight the potential of TCM as pharmaceutical sources.


'"/>

Contact: Janet Rettig Emanuel
janet.emanuel@yale.edu
203-432-2157
Yale University
5-Mar-2007


Page: 1 2

Related biology news :

1. UCF research links proteins, stem cells and potential Alzheimers treatment
2. Picky eating potentially perilous for bats
3. Scientists take next step in understanding potential target for ovarian cancer treatment
4. Nanoparticles hitchhike on red blood cells: a potential new method for drug delivery
5. Weill Cornell team identifies potential new cancer drug target
6. LIAI researchers identify a potential role for retinoic acid in autoimmune and inflammatory diseases
7. GM field trials underestimate potential for cross-pollination
8. New study suggests potential for a broadly-protective HIV vaccine
9. Hamilton College researchers discover molecules with potential to treat breast cancer
10. 8 plants from South Africa may hold potential for treating high blood pressure
11. TXNIP -- regulator of glucose homeostasis and potential diabetes drug target and more

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Triptolide potential drug for polycystic kidney disease

(Date:10/22/2014)... SAN JOSE, Calif. , Oct. 20, 2014 /PRNewswire/ ... with the United States Air Force Research Laboratory (AFRL), ... for Integrative Medicine (AzCIM) at the University of Arizona ... to receive research funding.  The AzCIM project,s goal is ... their ability to collect different volumes of sweat under ...
(Date:10/18/2014)... Among a group of 2,000 patients referred for ... a potential molecular diagnosis for 25 percent, including ... and new mutations contributing to disease, according to ... study is being released to coincide with the ... Whole-exome sequencing analyzes the exons or coding regions ...
(Date:10/17/2014)... release is available in German . ... a very few drugs. When treating overdoses, doctors are often ... especially difficult if there is a combination of drugs involved. ... and accidentally swallows his grandmother,s pills? ETH professor Jean-Christophe Leroux ... to find an answer to this question. "The task was ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3Whole-exome sequencing shows potential as diagnostic tool 2Emergency aid for overdoses 2Emergency aid for overdoses 3
(Date:10/25/2014)... DUBLIN , Oct 24, 2014 ... the "Epigenetics Market by Product , Research Area ... report to their offering. In ... the basis of products, research areas, and end users. ... this report are enzymes, instruments & consumables, kits, and ...
(Date:10/22/2014)... YORK , Oct. 22, 2014 New ... in the in vitro diagnostic (IVD) test industry, especially ... Information. The healthcare market researcher listed more than 25 testing ... could be the future of IVD products. Kalorama details the ... The Worldwide Market for In Vitro Diagnostic Tests ...
(Date:10/22/2014)... BOSTON , Oct. 22, 2014 /PRNewswire/ ... global specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, ... option to acquire Rhythm,s wholly owned subsidiary, Rhythm Health, ... agonist, for the treatment of diabetic gastroparesis and other ... a successful Phase 2 trial of relamorelin for the ...
(Date:10/22/2014)... (PRWEB) October 21, 2014 The North ... concerned market North America with analysis and forecast of ... 2013, and is expected to reach $623.6 million by ... 2018. , Browse through the TOC of the North ... of the in-depth analysis provided. This also provides a ...
Breaking Biology Technology:Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 3Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4
Cached News: